Organon & Co
USUSDOrganon & Co (LSE:0A9W) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- organon.com
- Relazioni con gli Investitori
- organon.com/investor-relations/
- Settore
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Centrale
- Oss, United States
- Amministratore Delegato
- Joseph T. Morrissey
- Dipendenti
- 10 000
- Fondata
- 1923
- Azioni in Circolazione
- Flottante
- 242.99 Mln
- Capitalizzazione di Mercato
- 3.6 Mld USD
- Insider
- 0.46%
- Investitori Istituzionali
- 84.8%
- Settore (SIC)
- Pharmaceutical Preparations
- ISIN
- US68622V1061
- LEI
- 549300AMCKY57OK2CO56
- P/E
- 17.3
- Payout Ratio
- 8.6%
- FCF
- 567 Mln USD
- Pagamenti / FCF
- 3%
- Debito
- 8.55 Mld USD13 anni di FCF
- Serie di Dividendi
- 5 a.
- Utili, FCF e dividendi pagati — per i 12 mesi fino a 30.06.2026 (l'ultimo rapporto dell'azienda).
- NAV
Descrizione
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Dividendi
Organon & Co (0A9W) paga dividendi trimestralmente. All'anno (12 mesi fino all'ultimo pagamento annunciato): 0.08 USD per azione (pagamenti: 4). Questo rappresenta circa il 0.58% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 17.11.2026. Storia dei dividendi ininterrotta: 5 anni.
| Data Ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-09-10 | 0.0200 USD | 0.1/0.6 % | trimestrale | LSE:0A9W |
| 2026-05-11 | 2026-06-11 | 0.0200 USD | 0.2/0.6 % | trimestrale | LSE:0A9W |
| 2026-02-23 | 2026-03-12 | 0.0200 USD | 0.3/1.0 % | trimestrale | LSE:0A9W |
| 2025-11-20 | 2025-12-11 | 0.0200 USD | 0.3/4.6 % | trimestrale | LSE:0A9W |
| 2025-08-15 | 2025-09-11 | 0.0200 USD | 0.2/6.5 % | trimestrale | LSE:0A9W |
| 2025-05-12 | 2025-06-12 | 0.0200 USD | 0.2/9.7 % | trimestrale | LSE:0A9W |
| 2025-02-21 | 2025-03-13 | 0.2800 USD | 1.8/7.2 % | trimestrale | LSE:0A9W |
| 2024-11-12 | 2024-12-12 | 0.2800 USD | 1.5/6.0 % | trimestrale | LSE:0A9W |
| 2024-08-16 | 2024-09-12 | 0.2800 USD | 1.5/6.0 % | trimestrale | LSE:0A9W |
| 2024-05-10 | 2024-06-13 | 0.2800 USD | 1.5/6.0 % | trimestrale | LSE:0A9W |
| 2024-02-23 | 2024-03-14 | 0.2800 USD | 1.5/6.0 % | trimestrale | LSE:0A9W |
| 2023-11-10 | 2023-12-14 | 0.2800 USD | 2.4/9.8 % | trimestrale | LSE:0A9W |
| 2023-08-17 | — | 0.2800 USD | 1.2/4.9 % | trimestrale | LSE:0A9W |
| 2023-05-12 | — | 0.2800 USD | 1.3/5.3 % | trimestrale | LSE:0A9W |
| 2023-02-24 | — | 0.2800 USD | 1.1/4.2 % | trimestrale | LSE:0A9W |
| 2022-11-10 | — | 0.2800 USD | 1.2/4.7 % | trimestrale | LSE:0A9W |
| 2022-08-12 | — | 0.2800 USD | 0.9/3.5 % | trimestrale | LSE:0A9W |
| 2022-05-13 | — | 0.2800 USD | 0.8/2.4 % | trimestrale | LSE:0A9W |
| 2022-02-25 | — | 0.2800 USD | 0.8/1.6 % | trimestrale | LSE:0A9W |
| 2021-11-19 | — | 0.2800 USD | 0.9/0.9 % | trimestrale | LSE:0A9W |
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| Blackrock Inc. | 12.21% | 32.06 Mln | 2026-06-30 |
| Pentwater Capital Manage… | 6.89% | 18.1 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 6.09% | 16 Mln | 2026-08-31 |
| Vanguard Portfolio Manag… | 5.76% | 15.13 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 4.54% | 11.91 Mln | 2026-06-30 |
| State Street Corporation | 3.68% | 9.66 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 8.33 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.29% | 6.02 Mln | 2026-06-30 |
| Goldman Sachs Group Inc | 1.98% | 5.2 Mln | 2026-06-30 |
| UBS Group AG | 1.85% | 4.86 Mln | 2026-06-30 |
| Geode Capital Management… | 1.83% | 4.82 Mln | 2026-06-30 |
| Alliancebernstein L.P. | 1.81% | 4.75 Mln | 2026-06-30 |
| Man Group PLC | 1.59% | 4.18 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.45% | 3.82 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 3.01 Mln | 2026-06-30 |
| NexPoint Funds I-NexPoin… | 1.03% | 2.71 Mln | 2026-06-30 |
| SPDR SERIES TRUST-State… | 0.94% | 2.47 Mln | 2026-08-31 |
| iShares Trust-iShares S&… | 0.89% | 2.35 Mln | 2026-08-31 |
| SPDR SERIES TRUST-State… | 0.54% | 1.41 Mln | 2026-08-31 |
| Fidelity Concord Street… | 0.49% | 1.3 Mln | 2026-07-31 |
| ALI KEVIN (Chief Executi… | ≈0.11% | 282 731 | 2025-05-05 |
| WALSH MATTHEW M (Chief F… | ≈0.08% | 212 746 | 2026-03-31 |
| MORRISSEY JOSEPH T JR (C… | ≈0.05% | 123 123 | 2026-03-31 |
| STAHLER RACHEL A (Chief… | ≈0.04% | 116 105 | 2026-03-31 |
| FALCIONE AARON (Officer) | ≈0.04% | 101 431 | 2026-03-31 |
| WEAVER KIRKE (General Co… | ≈0.04% | 92 639 | 2026-03-31 |
| NISITA VITTORIO (Officer… | ≈0.03% | 70 619 | 2026-03-31 |
| KARP DANIEL (Officer) | ≈0.03% | 69 547 | 2026-03-31 |
| HOLZBAUR LYNETTE (Office… | ≈0.02% | 52 850 | 2026-05-06 |
| COX CARRIE SMITH (Office… | — | — | 2025-11-12 |
